|Other Names||Fructosamine-3-kinase, 271-, FN3K|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7083a was selected from the N-term region of human FN3K. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May initiate a process leading to the deglycation of fructoselysine and of glycated proteins. May play a role in the phosphorylation of 1-deoxy-1-morpholinofructose (DMF), fructoselysine, fructoseglycine, fructose and glycated lysozyme.|
|Tissue Location||Expressed in erythrocytes.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FN3K catalyzes phosphorylation of fructosamines formed by glycation, the nonenzymatic reaction of glucose with primary amines followed by Amadori rearrangement. Phosphorylation of fructosamines may initiate metabolism of the modified amine and result in deglycation of glycated proteins. Human and mouse FN3K share 86% amino acid identity. GENE Purified FN3K catalyzes ATP-dependent phosphorylation of a synthetic fructosamine, 1-deoxy-1-morpholinofructose (DMF). Recombinant mouse and human FN3K, expressed in E. coli, catalyze phosphorylation of DMF, fructoselysine, fructoseglycine, and fructose in order of decreasing affinity. They also phosphorylate glycated lysozyme, but not unmodified lysozyme. In addition to ATP, FN3K can utilize GTP, CTP, and UTP as phosphate donors.
Conner, J.R., et al., Biochem. Biophys. Res. Commun. 323(3):932-936 (2004).Delpierrre, G., et al., J. Biol. Chem. 279(26):27613-27620 (2004).Szwergold, B.S., et al., Diabetes 50(9):2139-2147 (2001).Delpierre, G., et al., Diabetes 49(10):1627-1634 (2000).Delpierre, G., et al., Biochem. Soc. Trans. 31 (PT 6), 1354-1357 (2003) (): ().
If you have any additional inquiries please email technical services at email@example.com.